A report commissioned by the forestry biotech company suggests Rubicon's share price should be more than double its current level.
Hamish McNicol Fri, 10 Apr 2015
The share price of forestry biotech company Rubicon [NZX: RBC] should be “well above current levels,” a research report commissioned by the company says.
An Edison Investment Research report on the company, which was spun out of the old Fletcher Challenge, says the market is undervaluing its two
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).